AbbVie

AbbVie’s pharmaceutical portfolio

AbbVie develops and sells medicines across several treatment areas. Its results depend on the performance of individual products, their competitive position and how the portfolio changes over time.

A pharmaceutical company’s share is different from a direct investment in one research study. Existing product cash flows can support development, but they do not guarantee the success of the next programme.

Patents and replacing mature products

Patent expiry and competition can change the income produced by a previously important medicine. New launches need time, manufacturing capability and suitable market access to replace that contribution.

List prices, negotiated discounts and reimbursement all affect the net economics of sales. Changes in product mix can move margins differently from total revenue.

Research results and valuation

Study outcomes can change expectations before a medicine is approved or sold. Developing or acquiring programmes also requires capital. Eli Lilly and Johnson & Johnson provide different portfolios for comparison. Assess a research announcement against how much future revenue the market already expected, as well as the technical progress it reports.

Updated 2 November 2026